Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: ATV-1601 * Oral ATV-1601 Drug: Fulvestrant * Intramuscular Injection”In the company’s words, NCT07038369 on ClinicalTrials.gov
- Tested for
- Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease, Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers and 21 more
- Main trialPhase 1/2
- “This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.”In the company’s words, NCT07601425 on ClinicalTrials.gov
- Other names
- Active drug · capsule
Other drugs for Hereditary Hemorrhagic Telangiectasia (HHT)
- EngasertibVaderis Therapeutics AG · Phase 3
- DIAG723Diagonal Therapeutics, Inc. · Phase 1/2
- ALN-6400Alnylam · Phase 1/2
- TX002100Tectonic Operating Company, Inc. · Phase 1
Coming up2
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Aug 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2027 | Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) | |
| Phase 1Active, not recruiting | 31 Aug 2028 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026